Cell-free DNA molecules are released into the plasma via apoptotic or necrotic events and active release mechanisms, which carry the genetic and epigenetic information of its origin tissues. However, cfDNA is the mixture of various cell fragments, and the efficient enrichment of cfDNA fragments with diagnostic value remains a great challenge for application in the clinical setting. Evidence from recent years shows that cfDNA fragmentomics’ characteristics differ in normal and diseased individuals without the need to distinguish the source of the cfDNA fragments, which makes it a promising novel biomarker. Moreover, cfDNA fragmentomics can identify tissue origins by inferring epigenetic information. Thus, further insights into the fragmentom...
Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode of 166 bp. D...
Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alter...
Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alter...
Analysis of cell-free DNA (cfDNA) in the blood has shown promise for monitoring a variety of biologi...
The release of fetoplacental cell-free DNA (cfDNA) into the maternal bloodstream opened up new avenu...
Cell-free DNA (cfDNA) emerges as a promising liquid biopsy biomarker for cancer diagnosis and patien...
Circulating tumor DNA (ctDNA) in blood plasma is present at very low concentrations compared to cell...
To unequivocally address their unresolved intimate structures in blood, we scrutinized the size dist...
Cell-free DNA (cfDNA) is short, extracellular, fragmented double-stranded DNA found in plasma. Plasm...
Aim: The fragmentation characteristics of cell-free DNA (cfDNA) are informative biomarkers in liquid...
ABSTRACT Three-dimensional chromatin organization varies across cell types and is essential for gene...
Noninvasive sampling of an individual’s body fluids is an easy means to capture circulating cell-fre...
Cell-free DNA (cfDNA) emerges as a promising liquid biopsy biomarker for cancer diagnosis and patien...
BACKGROUND: High-throughput sequencing of cell-free DNA fragments found in human plasma has been use...
Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode of 166 bp. D...
Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode of 166 bp. D...
Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alter...
Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alter...
Analysis of cell-free DNA (cfDNA) in the blood has shown promise for monitoring a variety of biologi...
The release of fetoplacental cell-free DNA (cfDNA) into the maternal bloodstream opened up new avenu...
Cell-free DNA (cfDNA) emerges as a promising liquid biopsy biomarker for cancer diagnosis and patien...
Circulating tumor DNA (ctDNA) in blood plasma is present at very low concentrations compared to cell...
To unequivocally address their unresolved intimate structures in blood, we scrutinized the size dist...
Cell-free DNA (cfDNA) is short, extracellular, fragmented double-stranded DNA found in plasma. Plasm...
Aim: The fragmentation characteristics of cell-free DNA (cfDNA) are informative biomarkers in liquid...
ABSTRACT Three-dimensional chromatin organization varies across cell types and is essential for gene...
Noninvasive sampling of an individual’s body fluids is an easy means to capture circulating cell-fre...
Cell-free DNA (cfDNA) emerges as a promising liquid biopsy biomarker for cancer diagnosis and patien...
BACKGROUND: High-throughput sequencing of cell-free DNA fragments found in human plasma has been use...
Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode of 166 bp. D...
Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode of 166 bp. D...
Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alter...
Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alter...